Karen Tkach Tuzman

San Francisco, United States

Director of Biopharma Intelligence at BioCentury

Featured in: Favicon

biocentury.com Favicon

smdailyjournal.com Favicon

zephyrnet.com

Articles

Heranova: Detecting endometriosis in the blood like it’s cancer

4 weeks ago | biocentury.com | Karen Tkach Tuzman

ARTICLE | Emerging Company Profile The Massachusetts-based company launched a microRNA-based liquid biopsy test for endometriosis, with an eye toward disease monitoring and drug development By Karen Tkach Tuzman, Director of Biophrama Intelligence Heranova thinks the similarities between endometriosis and cancer will make the notoriously difficult-to-diagnose disease amenable to non-invasive detection via liquid biopsy of nucleic acids from uterine lining cells undergoing excessive growth,...
Tempus aims for precision in complexity

1 month ago | biocentury.com | Karen Tkach Tuzman

ARTICLE | Product DevelopmentWith clinical records, patient samples and images in the millions, the diagnostics and data company is betting precision medicine can go multimodal By Karen Tkach Tuzman, Director of Biopharma IntelligenceTempus thinks it has the scale of data needed to deliver on the idea that the next era of precision medicine will go beyond single biomarkers to provide more holistic views of patients and their predicted responses to drugs.
Telix’s end-to-end radiopharma ambitions

1 month ago | biocentury.com | Karen Tkach Tuzman

ARTICLE | Product DevelopmentWith a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey By Karen Tkach Tuzman, Director of Biopharma IntelligenceWhile most radiopharma companies are focused on a particular radioisotope platform or ligand modality, Telix is using a range of technologies to tailor therapeutic-diagnostic pairs for specific indications.
No causal biology without diversity: a Perspective

2 months ago | biocentury.com | Karen Tkach Tuzman

ARTICLE | Editor's Commentary As human data are poised to deliver causal targets and more precise interventions, caving to anti-DEI rhetoricin science is a costly mistake By Karen Tkach Tuzman, Director of Biopharma Intelligence Amid the Trump administration’s looming threats to slash NIH and its funding of academic institutions, there is a subtler but no less disruptive shift permeating translational research — the growing sense among U.S. investigators that they will be punished for...
Pain targets in ion channel pathways: an Innovation Distillery spotlight

2 months ago | biocentury.com | Karen Tkach Tuzman

ARTICLE | Discovery & TranslationUpstream regulators of ion channel expression or function are an emerging frontier for novel pain targets By Karen Tkach Tuzman, Director of Biopharma Intelligence and Elizabeth Stivison, BioCentury StaffWith Vertex’s recent FDA approval marking the first new class of pain drug in over 20 years, the aperture is opening for mechanisms of action outside dominant paradigms.
The radiopharma landscape takes shape in neuroendocrine tumors

2 months ago | biocentury.com | Karen Tkach Tuzman

ARTICLE | Product DevelopmentItm and Perspective’s readouts are the latest clinical advances in GEP-NETs, the first indication to put radioligand therapies on the map By Karen Tkach Tuzman, Director of Biopharma IntelligenceNovartis’ Lutathera made gut and pancreatic neuroendocrine tumors a bright spot for radiopharma, and at least five clinical-stage competitors are advancing behind it.
How VCs at the AI-bio interface set up their portfolios for success

Jan 14, 2025 | biocentury.com | Karen Tkach Tuzman

ARTICLE | FinanceSome firms are playing an active role in overcoming data starvation and bolstering the infrastructure ecosystem By Karen Tkach Tuzman, Director of Biopharma IntelligenceWhile life science VCs have long provided operational support to portfolio companies, the specific bottlenecks and opportunties at the AI interface are motivating some firms to take a more proactive role in supplying inputs such as data, analytics and tools, either directly or through other investments.
Life science VCs driving AI innovation: the view from the interface in 2025

Jan 9, 2025 | biocentury.com | Karen Tkach Tuzman

ARTICLE | Finance How VC firms focused on AI-driven drug development think about the resources and strategies needed to turn promise into reality By Karen Tkach Tuzman, Director of Biopharma Intelligence As AI becomes an increasingly ubiquitous part of daily life, the longstanding question of its impact on drug development is less “whether” than “how.” VC firms that have made this question a core part of their thesis are meeting the moment with different strategies, ranging from providing...
Where the Ratio deal fits into Novartis’ radiopharma matrix

Nov 19, 2024 | biocentury.com | Karen Tkach Tuzman

ARTICLE | DealsThe deal grows Novartis’ ligand modality and chelator toolbox, and its focus on Lutathera target SSTR2 By Karen Tkach Tuzman, Director of Biopharma IntelligenceBeyond the big acquisitions that put Novartis on the map as a radiopharmaceutical trailblazer are strings of smaller deals providing specialized subcomponents for the modular modality.
Archon: Tuning antibodies through geometry

Nov 14, 2024 | biocentury.com | Karen Tkach Tuzman

ARTICLE | Emerging Company ProfileLatest spinout from David Baker’s IPD rescuing failed mAbs by forcing them into cage-like structures for better biodistribution, target engagement By Karen Tkach Tuzman, Director of Biopharma IntelligenceArchon is packing antibodies into computationally designed geometries to better control their activity, with the goal of addressing well-understood targets failed by free mAbs. The company, which emerged from stealth Oct.